Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Patients with BRCA mutations often face aggressive disease and poor prognosis
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
